ArticleScientific reports2025
Metabolic profiles of squamous cell lung carcinoma and diagnostic model construction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer cells exhibit metabolic reprogramming to fulfill their increased demands for abnormal growth and proliferation. We studied metabolic profiles of squamous cell lung carcinoma (LUSC).Elevated arginine levels and reduced acylcarnitine C18:2, along with decreased phosphatidylcholine (PC) with acyl-alkyl residues C38:0 were associated with the diagnosis and prognosis of LUSC. Most of the PCs demonstrated a decrease, while lysophosphatidylcholines (LPC) exhibited an increase in LUSC patients. Network analysis unveiled that LPCs mediated PC and amino acids subgroup in LUSC compared to the control group. Analysis of public LUSC data confirmed associations between the expression levels of genes encoding enzymes involved in the biosynthesis pathways of arginine, proline (ASL, OTC, PYCR2), PC (CEPT1, CHPT1, LPCAT1) and LPC (LCAT, PLA2G16, PLB1) with a 5-yr survival outcome. The observed metabolic reprogramming in LUSC patients suggested the potential utility of metabolites as a supportive biomarkers for LUSC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.